E. Jason Abel, MD, FACS Print Friendly Page
Faculty, University of Wisconsin School of Medicine and Public HealthDr. Abel is board certified by the American Board of Urology and specializes in the surgical treatment of urologic malignancies. He has advanced training to surgically manage all types of genitourinary cancers, including prostate cancer, bladder cancer, kidney cancer, testis cancer and penile cancer.
Dr. Abel performs open and laparoscopic surgery, including surgery using the daVinci robot. His philosophy is to provide maximal quality of life to patients by using minimally invasive approaches to cancer therapy whenever appropriate. He has a special interest in the treatment of localized and locally advanced kidney cancer.
Specialties
Clinics
Hospital Affiliation(s)
UW School of Medicine and Public Health
Department of Urology |
Professional Certifications and Education
Board Certification |
Urology
|
Fellowship |
Urologic Oncology, M.D. Anderson Cancer Center, Houston, TX |
Residency |
University of Utah Hospital, Salt Lake City, UT
|
Internship |
University of Utah Hospital, Salt Lake City, UT
|
Medical School |
University of Texas Medical School, Houston, TX
|
Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000. |
Research |
Dr. Abel conducts clinical, translational and basic research in urologic oncology. He currently is involved in several projects focusing on the development and metastasis of kidney cancer. |
PubMed Articles
-
Chipollini J Abel EJ Peyton CC Boulware DC Karam JA Margulis V Master VA Zargar-Shoshtari K Matin SF Sexton WJ Raman JD Wood CG Spiess PE
Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration. Clin Genitourin Cancer . 2018 Apr;16(2):e443-e450
[PubMed ID: 29113770]
-
Richards KA Ruiz VL Murphy DR Downs TM Abel EJ Jarrard DF Singh H
Diagnostic evaluation of patients presenting with hematuria: An electronic health record-based study. Urol Oncol . 2018 Mar;36(3):88.e19-88.e25
[PubMed ID: 29169843]
-
Hutchinson R Rew C Chen G Woldu S Krabbe LM Meissner M Sheth K Singla N Shakir N Master VA Karam JA Matin SF Borregales LD Wood C Masterson T Thompson RH Boorjian SA Leibovich BC Abel EJ Bagrodia A Margulis V
The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus. Urology . 2018 Feb 27;
[PubMed ID: 29499258]
-
Maciolek KA Abel EJ Best SL Emamekhoo H Averill SL Ziemlewicz TJ Lubner MG Hinshaw JL Lee FT Jr. Wells SA
Percutaneous microwave ablation for local control of metastatic renal cell carcinoma. Abdom Radiol (NY) . 2018 Feb 20;
[PubMed ID: 29464274]
-
Miller BL Mankowski Gettle L Van Roo JR Ziemlewicz TJ Best SL Wells SA Lubner MG Hinshaw JL Lee FT Jr. Nakada SY Huang W Abel EJ
Comparative Analysis of Surgery, Thermal Ablation, and Active Surveillance for Renal Oncocytic Neoplasms. Urology . 2018 Feb;112:92-97
[PubMed ID: 29030073]
-
Miller BL Abel EJ
Editorial Comment. J Urol . 2017 Dec 8;
[PubMed ID: 29227803]
-
Maciolek KA Jarrard DF Abel EJ Best SL
Systematic Assessment Reveals Lack of Understandability for Prostate Biopsy Online Patient Education Materials. Urology . 2017 Nov;109:101-106
[PubMed ID: 28780302]
-
Abel EJ Masterson TA Karam JA Master VA Margulis V Hutchinson R Lorentz CA Bloom E Bauman TM Wood CG Blute ML Jr
Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus. J Urol . 2017 Oct;198(4):810-816
[PubMed ID: 28411071]
-
Damodaran S Abel EJ
Editorial Comment. Urology . 2017 Oct;108:121
[PubMed ID: 28807653]
-
Blute ML Jr Kucherov V Rushmer TJ Damodaran S Shi F Abel EJ Jarrard DF Richards KA Messing EM Downs TM
Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m<sup>2</sup> ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression. BJU Int . 2017 Sep;120(3):387-393
[PubMed ID: 28464520]
-
Shapiro DD Abel EJ
Editorial Comment. J Urol . 2017 Sep;198(3):537
[PubMed ID: 28641080]
-
Best SL Abel EJ
Editorial Comment. J Urol . 2017 Aug;198(2):295
[PubMed ID: 28527306]
-
Abel EJ Spiess PE Margulis V Master VA Mann M Zargar-Shoshtari K Borregales LD Sexton WJ Patil D Matin SF Wood CG Karam JA
Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. J Urol . 2017 Aug;198(2):281-288
[PubMed ID: 28268170]
-
Klapperich ME Abel EJ Ziemlewicz TJ Best S Lubner MG Nakada SY Hinshaw JL Brace CL Lee FT Jr Wells SA
Effect of Tumor Complexity and Technique on Efficacy and Complications after Percutaneous Microwave Ablation of Stage T1a Renal Cell Carcinoma: A Single-Center, Retrospective Study. Radiology . 2017 Jul;284(1):272-280
[PubMed ID: 28076721]
-
Wells SA Wong VK Wittmann TA Lubner MG Best SL Ziemlewicz TJ Hinshaw JL Lee FT Jr Abel EJ
Renal mass biopsy and thermal ablation: should biopsy be performed before or during the ablation procedure? Abdom Radiol (NY) . 2017 Jun;42(6):1773-1780
[PubMed ID: 28184961]
-
Tazeh NN Canter DJ Damodaran S Rushmer T Richards KA Abel EJ Jarrard DF Downs TM
Neutrophil to Lymphocyte Ratio (NLR) at the Time of Transurethral Resection of Bladder Tumor: A Large Retrospective Study and Analysis of Racial Differences. Bladder Cancer . 2017 Apr 27;3(2):89-94
[PubMed ID: 28516153]
-
Best SL Blute M Jr Lane B Abel EJ
Surgical Treatment of 4-10 cm Renal-Cell Carcinoma: A Survey of the Lions and Gazelles. J Endourol . 2017 Apr;31(S1):S43-S47
[PubMed ID: 28326796]
-
Wittmann TA Abel EJ
Percutaneous biopsy in large, locally advanced or metastatic renal tumors. Urol Oncol . 2017 Mar;35(3):87-91
[PubMed ID: 27889280]
-
Blute ML Jr Damaschke N Wagner J Yang B Gleave M Fazli L Shi F Abel EJ Downs TM Huang W Jarrard DF
Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy. PLoS One . 2017;12(2):e0172048
[PubMed ID: 28234906]
-
Blute ML Jr Ziemlewicz TJ Lang JM Kyriakopoulos C Jarrard DF Downs TM Grimes M Shi F Mann MA Abel EJ
Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis. Urology . 2017 Feb;100:139-144
[PubMed ID: 27667156]